INKT
MiNK Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 27 to Mar 10 ▼ 4 days of insider sells: $27.5K by 1 insider, avg $13.74
- Apr 17 ▲ MiNK Therapeutics announced positive Phase II trial data for its age…
- May 14 ▲ MiNK Therapeutics announced the initiation of a randomized Phase 2 t…
- May 15 ▲ MiNK Therapeutics reported Q1 2026 EPS of -$0.57, beating consensus…
- May 20 FDA: MiNK Therapeutics Reports New Data on agenT-797, an allo-i…
- May 28 FDA: MiNK Therapeutics Announces First Patient Dosed in Randomi…
- Jun 4 ▼ 1 insider sell $19.1K at $12.76
- Aug 6 ▲ MiNK Therapeutics presented initial Phase 2 data at MHSRS showing fi…
- Aug 6 FDA: MiNK Therapeutics Presents Early Observations from Ongoing…
- Aug 13 MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share),…
- Oct 2 FDA: MiNK Therapeutics to Present Data on Treatment-Resistant C…
- Oct 12 ▼ 1 insider sell $73.3K at $10.56
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $119.9K.
- InstitutionsMIXED
Q3 2026: 3 added (0 new), 1 trimmed or exited.
- AnalystsBULLISH
7 of 8 rate it Buy or better. Every target is above the price.
- EstimatesFLAT
Current-quarter EPS estimate −$0.660 → −$0.670 over 90 days. 1 up, 0 down in 30 days.
- Short sellersBUILDING
Short interest +15.3% to 55.1K shares. 4.3 days to cover, ≈1.1% of shares.
- TrendDOWNTREND
15% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD FIDUCIARY TRUST CO | ADD | $165.2K |
| UBS Group AG | TRIM | $18.3K |
| BlackRock, Inc. | DOUBLED | $156.4K |
| UBS Group AG | TRIM | $57.1K |
| OSAIC HOLDINGS, INC. | DOUBLED | $1.4K |
| UBS Group AG | ADD | $160.1K |
| CITIGROUP INC | TRIM | $958.00 |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | $10.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
8 analystsPrice is below the lowest target. Median implies +371%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 21, 2026 | B. Riley Securities REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Buell Jennifer Chief Executive Officer Oct 12, 2026 | SELL | $73.3K |
Buell Jennifer Chief Executive Officer Oct 11, 2026 | EXERCISE | 23,191 sh |
Behner Peter Director Sep 1, 2026 | AWARD | $16.3K |
Ryan Barbara Director Sep 1, 2026 | AWARD | $17.8K |
Holcomb John Bradley Director Sep 1, 2026 | AWARD | $13.5K |
Corvese Brian Director Sep 1, 2026 | AWARD | $17.9K |
WIINBERG ULF Director Sep 1, 2026 | AWARD | $14.0K |
Ryan Barbara Director Jun 4, 2026 | SELL | $6.3K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.67 | -$0.71–-$0.63 | -71.8% | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | -$2.45 | -$2.58–-$2.32 | -26.9% | $0.00 |
| Next FY | -$0.72 | -$0.72–-$0.72 | +63.5% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 11 press releases · 2 bullish · 0 bearish · 2 mixed · 6 neutral- NEUTRAL 8-KNov 12, 2026
MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50/share), a 23% year-over-year…
Monitor U.S. site activation and dosing in the randomized ARDS trial before year-end, and the FDA meeting on the adaptive Phase 2b/3 design. The named-patient revenue stream is small and variable…
- NEUTRAL PRESS-RELEASENov 11, 2026
MiNK Therapeutics reported Q3 2026 net loss of $2.6M ($0.50 per share), narrower than the $2.9M…
Monitor U.S. site activation and dosing in the randomized ARDS trial before year-end, and any FDA feedback on the adaptive Phase 2b/3 design. The company's cash runway ($7.5M) and operating burn…
- NEUTRAL PRESS-RELEASENov 2, 2026
MiNK Therapeutics announced it will report Q3 2026 financial results on November 11, 2026, before…
Monitor the November 11 earnings call for actual Q3 financials, cash runway update, and clinical milestones for agenT-797. The stock's small market cap ($55M) makes it sensitive to trial readouts…
- NEUTRAL 144Oct 13, 2026
Jennifer Buell, President and CEO of MiNK Therapeutics, filed a Form 144 notice to sell 6,938…
This is a routine sell-to-cover transaction for tax withholding on RSU vesting, not a discretionary insider sale. No bearish signal. Monitor the Form 4 filing to confirm execution and any change in…
All INKT filing & press-release reports (21)
- 8-K reportNov 12, 2026
- PRESS-RELEASE reportNov 11, 2026
- PRESS-RELEASE reportNov 2, 2026
- 144 reportOct 13, 2026
- PRESS-RELEASE reportOct 2, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- PRESS-RELEASE reportAug 6, 2026
- PRESS-RELEASE reportMay 28, 2026
- PRESS-RELEASE reportMay 20, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportMay 14, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMay 8, 2026
- 8-K reportMar 31, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 1, 2026
- PRESS-RELEASE reportMar 31, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026